BDSI BioDelivery Sciences Internatio

1.65
+0  (3%)
Previous Close 1.60
Open 1.60
Price To book 0.00
Market Cap 90.41M
Shares 54,796,000
Volume 195,152
Short Ratio 10.62
Av. Daily Volume 437,006

SEC filingsSee all SEC filings

  1. 8-K - Current report 17730971
  2. CT ORDER - Confidential treatment order 17714954
  3. 8-K/A (Amend) - Current report 17713107
  4. 8-K - Current report 17698835
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17695193

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released December 13, 2016 - primary endpoints not met.
Clonidine gel
Painful diabetic neuropathy (PDN)
Approved June 6, 2014.
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL
Opioid dependence
Approved October 26, 2015.
BEMA Buprenorphine
Pain

Latest News

  1. BioDelivery (BDSI) Down 15% Since Earnings Report: Can It Rebound?
  2. New cash, patents boost optimism at Raleigh's BioDelivery Sciences
  3. BioDelivery to Grant New Patents for its Marketed Drugs
  4. Blog Coverage BioDelivery Extends its Patent Portfolio; Acquires Extended Patents for BELBUCA, BUNAVIL, and ONSOLIS
  5. BioDelivery Sciences Secures Two Patents
  6. BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in FDA's Orange Book Further Extending and Strengthening Patent Protection on BELBUCA®, BUNAVAIL® and ONSOLIS®
  7. BioDelivery Sciences International and Rexahn Pharmaceuticals See Share Values Rise Slightly
  8. BioDelivery (BDSI) Q4 Loss Wider Than Expected; Sales Meet
  9. Edited Transcript of BDSI earnings conference call or presentation 17-Mar-17 12:00pm GMT
  10. BioDelivery Q4 Loss Wider Than Expected; Revenues in Line
  11. BioDelivery reports 4Q loss
  12. BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
  13. BioDelivery Sciences Announces Three Data Presentations on BELBUCA® at the American Academy of Pain Medicine 33rd Annual Meeting
  14. BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2016 Financial Results on Friday, March 17
  15. BioDelivery Sciences to Present at the 29th Annual ROTH Conference
  16. Has Biodelivery Sciences Finally Turned the Corner?
  17. BioDelivery (BDSI): What's in Store this Earnings Season?
  18. Endo profit, sales beat as the drugmaker enters transition phase
  19. BioDelivery Sciences Secures Debt Financing with CRG
  20. Belbuca return expected to push BDSI to profitability sooner